Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

Also called NCT01499407

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
CLI Foundation (from the registry)
Registry
  • NCT NCT01499407
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01499407. Randomized; double masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2012-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction
Acronym
COCTAIL II
Condition
ST-elevation Myocardial Infarction
Intervention (Device)
ClearWay RX catheter
Intervention (Drug)
Abciximab
Lead sponsor
CLI Foundation (class: other)

Record details

Record id
cardio:ct-nct01499407
Content hash
e44150849a592aa4beb353865f95444d6047b097635e51af42287a5e8f743027